Results 61 to 70 of about 3,560 (171)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

open access: yesJournal of Hematology & Oncology, 2021
Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and
Heng Mei   +38 more
doaj   +1 more source

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I‐WISh) 2.0

open access: yesAmerican Journal of Hematology, Volume 101, Issue 8, Page 1954-1968, August 2026.
ABSTRACT Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment‐related burden. I‐WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients.
Nichola Cooper   +17 more
wiley   +1 more source

Romiplostim as a treatment for immune thrombocytopenia: a review

open access: yesJournal of Blood Medicine, 2015
Sarah Chalmers,1,2 Michael D Tarantino1–31University of Illinois College of Medicine – Peoria, 2The Children's Hospital of Illinois, 3The Bleeding and Clotting Disorders Institute, Peoria, Illinois, USAAbstract: “Immune ...
Chalmers S, Tarantino MD
doaj  

Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage

open access: yesPlatelets, 2017
We present here a 63-year old woman with a long history of immune thrombocytopenia. She was hospitalized for a traumatic intracranial hemorrhage with thrombocytopenia.
O. Espitia   +5 more
doaj   +1 more source

Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia

open access: yesNew England Journal of Medicine, 2011
A 26-year-old woman with a history of chronic primary immune thrombocytopenia presents for evaluation. Her condition was first diagnosed when she was 11 years of age. Her platelet count has typically been less than 10,000 per cubic millimeter. Her symptoms have not responded to glucocorticoids, and she has had only transient responses to intravenous ...
Imbach P, Crowther M
openaire   +3 more sources

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Efficacy and Safety of rhIL‐11 in the Treatment of Cancer Therapy‐Induced Thrombocytopenia: A Multicenter Retrospective Study

open access: yesCancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Objective This real‐world study aimed to investigate the cancer therapy‐induced thrombocytopenia (CTIT) profile and evaluate the efficacy and safety of recombinant human interleukin‐11 (rhIL‐11) in its management. Methods Retrospective analysis included 12,431 CTIT patients treated with rhIL‐11 across 58 Chinese centers (July 2023–June 2024 ...
Yingmei Wen   +13 more
wiley   +1 more source

New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents

open access: yesBiologics: Targets & Therapy, 2009
Ara Metjian1, Charles S Abrams21Department of Medicine, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USAAbstract: Decades of basic science and clinical research have led to an ...
Ara Metjian, Charles S Abrams
doaj  

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials

open access: yes
British Journal of Haematology, EarlyView.
Jong Wook Lee   +19 more
wiley   +1 more source

Risk of thrombosis and bleeding following CAR T‐cell therapy: Insights from the Dutch “Follow that CAR!” registry

open access: yesHemaSphere, Volume 10, Issue 7, July 2026.
Abstract Chimeric antigen receptor (CAR) T‐cell therapy has significantly improved outcomes in patients with relapsed/refractory aggressive large B‐cell lymphoma (R/R LBCL). Although thrombosis and bleeding complications have been increasingly reported, their clinical relevance and risk factors remain unclear, also due to heterogeneity between ...
Amica K. Ko   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy